Menu Search
Equities

Enorama Pharma AB

ERMA:STO

Enorama Pharma AB

Actions
  • Price (SEK)3.89
  • Today's Change0.00 / 0.00%
  • Shares traded641.00
  • 1 Year change+52.82%
  • Beta1.1711
Data delayed at least 15 minutes, as of Nov 26 2024 08:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Enorama Pharma AB's revenues fell -80.17% from 6.85m to 1.36m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 42.03m to a larger loss of 44.61m.
Gross margin-32.71%
Net profit margin-705.54%
Operating margin-682.30%
Return on assets-99.66%
Return on equity-160.87%
Return on investment-147.35%
More ▼

Cash flow in SEKView more

In 2023, Enorama Pharma AB increased its cash reserves by 48.66%, or 2.01m. Cash Flow from Financing totalled 41.86m or 3,082.70% of revenues. In addition the company used 41.35m for operations while cash from investing was breakeven.
Cash flow per share-0.837
Price/Cash flow per share--
Book value per share0.6408
Tangible book value per share0.3246
More ▼

Balance sheet in SEKView more

Enorama Pharma AB uses little debt in its capital structure as supported by a debt to capital ratio of 0.94%.
Current ratio2.74
Quick ratio2.00
Total debt/total equity0.0095
Total debt/total capital0.0094
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.